Back to the future: Research renewed on the clinical utility of psychedelic drugs

Abstract

Get full access to this article

View all access options for this article.

References

Alvir

Lieberman

Safferman

. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl J Med 329: 162–167.

Franks

Macpherson

Figg

(2004) Thalidomide. Lancet 363: 1802–1811.

Gao

Kong

Wang

. (2016) Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. Tumour Biol 37: 11081–11098.

González-Maeso

Ang

Yuen

. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452: 93–97.

Griffiths

Johnson

Carducci

. (2016) Psilocybin produces substantial and sustained decrease in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30: 1181-1197.

Hall

Lynskey

(2016) Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. Lancet Psychiatry 3: 900–906.

Hendricks

Thorne

Clark

. (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 29: 280–288.

Hofmann

Heim

Brack

. (1958) [Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]. Experientia 14: 107–109.

Johnson

Richards

Griffiths

(2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22: 603–620.

10.

Kane

Honigfeld

Singer

. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796.

11.

Kraehenmann

Preller

Scheidegger

. (2015) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 78: 572–581.

12.

Krebs

Johansen

P-Ø

(2013) Psychedelics and mental health: a population study. PLOS ONE 8: e63972.

13.

Newport

Carpenter

McDonald

. (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172: 950–966.

14.

Nichols

(2016) Psychedelics. Pharmacol Rev 68: 264–355.

15.

Nutt

King

Phillips

. (2010) Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558–1565.

16.

Nutt

King

Nichols

(2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14: 577–585.

17.

Ross

Bossis

Guss

. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30: 1165-1180.

18.

Rucker

JJH

(2015) Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ 350: h2902.

19.

Unger

(1963) Mescaline, LSD, psilocybin, and personality change. Psychiatry 26: 111–125.

20.

van Amsterdam

Opperhuizen

van den Brink

(2011) Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol 59: 423–429.

21.

Vargesson

(2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 105: 140–156.

22.

Vollenweider

Kometer

(2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11: 642–651.